The New Zealand government has proposed a new psychoactive substances regime, which will place the onus onto manufacturers to prove that their products pose a low risk of harm, prior to receiving approval which allows the products to be legally manufactured and sold. This is an innovative and unique development in the regulation of emerging psychoactive substances, and offers an alternative response to prohibition. The details of the new regime and how it will operate are now emerging, and this offers an opportunity to critically explore some of the issues related to the proposed new regime and to speculate on some of the outcomes. This paper brings together a group of New Zealand based researchers from a range of disciplines with experience of ‘legal high’ research to discuss this innovative new regime.
AdamsPJBuetowSRossenF (2010) Poisonous partnerships: Health sector buy-in to arrangements with government and addictive consumption industries. Addiction105: 585–590.
2.
AlansariMHamiltonD (2006) Nephrotoxicity of BZP-based herbal party pills: A New Zealand case report. N Z Med J119: No. 1233.
BaborTFMillerPEdwardsG (2010) Vested interests, addiction research and public policy. Addiction105: 4–5.
5.
BondLDaubeMChikritzhsT (2010) Selling addictions: Similarities in approaches between big tobacco and big booze. Australas Med J3: 325–332.
6.
ButlerRSheridanJ (2007) Highs and lows: Patterns of use, positive and negative effects of benzylpiperazine-containing party pills (BZP-party pills) amongst young people in New Zealand. Harm Reduct J4. doi:10.1186/1477-7517-4-18.
7.
ChapmanSShatensteinS (2001) The ethics of the cash register: Taking tobacco research dollars. Tob Control10: 1–2.
8.
CohenBMZButlerR (2011) BZP-party pills: A review of research on benzylpiperazine as a recreational drug. Int J Drug Policy22: 95–101.
9.
CromerJRCromerJAMaruffP. (2010) Perception of alcohol intoxication shows acute tolerance while executive functions remain impaired. Exp Clin Psychopharmacol18: 329–339.
10.
DawkinsK (2008) The great BZP hoax. N Z Law JJuly: 250–253.
EverittBJRobbinsTW (2005) Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat Neurosci8: 1481–1489.
13.
Expert Advisory Committee on Drugs (EACD) (2004) The Expert Advisory Committee on Drugs (EACD) advice to the minister on: benzylpiperazibe (BZP). Wellington, New Zealand: EACD.
GeePRichardsonSWoltersdorfW. (2005) Toxic effects of BZP-based herbal party pills in humans: A prospective study in Christchurch, New Zealand. N Z Med J118: No. 1784.
17.
HaddadPMDursunSM (2008) Neurological complications of psychiatric drugs: Clinical features and management. Hum Psychopharmacol23: S15–S26.
18.
HaganHThiedeHDes JarlaisDC (2005) HIV/hepatitis C virus co-infection in drug users: Risk behavior and prevention. AIDS19: S199–S207.
19.
KalaposMP (2002) Carbamazepine-provoked hepatotoxicity and possible aetiopathological role of glutathione in the events. Retrospective review of old data and call for new investigation. Adverse Drug React Toxicol Rev21: 123–141.
20.
LevinEDRezvaniAH (2002) Nicotinic treatment for cognitive dysfunction. Curr Drug Targets CNS Neurol Disord1: 423–431.
21.
LuomaJBTwohigMPWaltzT. (2007) An investigation of stigma in individuals receiving treatment for substance abuse. Addict Behav32: 1331–1346.
MillerPGde GrootFMckenzieS. (2011) Alcohol industry use of social aspect public relations organisations against preventative health measures. Addiction106: 1560–1567.
Ministry of Health (2012) Regulatory Impact Statement - New regulatory regime for psychoactive substances. Wellington, New Zealand.
26.
New Zealand Government Agency (2011) New psychoactive substances. In: Controlling and Regulating Drugs – A Review of the Misuse of Drugs Act 1975. Wellington, New Zealand, pp. 114–148.
27.
NicholsonTC (2006) Prevalence of use, epidemiology and toxicity of ‘herbal party pills’ among those presenting to the emergency department. Emerg Med Australas18: 180–184.
28.
Office of the Associate Minister of Health and Cabinet Social Policy Committee (2012a) Regulation of psychoactive substances. Wellington, New Zealand: New Zealand Government Reports.
29.
Office of the Associate Minister of Health and Cabinet Social Policy Committee (2012b) Regulation of Psychoactive Substances - further policy decisions. Wellington, New Zealand.
SheridanJButlerR (2007) Legal party pills and their use by young people in New Zealand: A qualitative study. Final report of findings (revised June2007). Auckland, New Zealand: Faculty of Health Sciences, University of Auckland.Available at: http://www.ndp.govt.nz/moh.nsf/pagescm/7493/$File/legalpartypills-use-jun08.pdf.
34.
SheridanJButlerR (2009) ‘They’re so legal they’re safe, right?’ What did the legal status of BZP-party pills mean to young people in New Zealand?Int J Drug Policy21: 77–81
35.
SheridanJAtmoreBRussellB (2012) New Zealand to establish fit for purpose regulation for new psychoactive substances (Commentary). Addiction107: 1901–1902.
36.
SheridanJButlerRWilkinsC. (2007) Legal piperazine-containing party pills – a new trend in substance misuse. Drug Alcohol Rev26: 335–343.
37.
StinglJCBrockmollerJVivianiR (2013) Genetic variability of drug-metabolizing enzymes: The dual impact on psychiatric therapy and regulation of brain function. Mol Psychiatry. 18: 273–287
38.
Treasury (2011) Regulatory impact statement - Government response to the Law Commission’s report ‘Controlling and Regulating Drugs – a review of the Misuse of Drugs Act 1975’. Wellington, New Zealand.
39.
WhiteJMIrvineRJ (1999) Mechanisms of fatal opioid overdose. Addiction94: 961–972.
40.
WilkinsC (2011) A paradigm shift in recreational drug use: the challenge of legal highs in New Zealand [Letter]. N Z Med J124 (1339): 99–101.
41.
WilkinsCSweetsurP (2010) Differences in harm from legal BZP/TFMPP party pills between North Island and South Island users in New Zealand: A case of effective industry self regulation?Int J Drug Policy21: 86–90.
42.
WilkinsCSweetsurP (2013) The impact of the prohibition of benzylpiperazine (BZP) ‘legal highs’ on the prevalence of BZP, new legal highs and other drug use in New Zealand. Drug Alcohol Depend127: 72–80
43.
WilkinsCGirlingMSweetsurP (2007) The prevalence of use, dependency and harms of legal party pills containing benzylpiperazine (BZP) and trifluorophenylmethylpiperazine (TFMPP) in New Zealand. J Subst Use12: 213–224.
44.
WilkinsCSweetsurPGirlingM (2008) Patterns of benzylpiperazine/trifluoromethylphenylpiperazine party pill use and adverse effects in a population sample in New Zealand. Drug Alcohol Rev27: 633–639.
45.
WilkinsCSweetsurPSmartB. (2012) Recent trends in illegal drug use in New Zealand: Findings from the 2006, 2007, 2008, 2009, 2010 and 2011 Illicit Drug Monitoring System (IDMS). Auckland: SHORE, Massey University.
46.
WinstockARRamseyJD (2010) Legal highs and the challenges for policy makers. Addiction105: 1685–1687.
